Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis Advanced analysis of neuroimaging features associated with ...
Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatments To accelerate partnering efforts with global pharmaceutical ...
Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD Company accelerates partnerships with global ...
Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key solutions Collaboration expected to leverage Neurophet AQUA, Neurophet SCALE PET and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results